Martin Shkreli's old companies secure $650,000 deal to sell Daraprim amid bankruptcy
Daraprim, the anti-malarial and anti-parasitic at the heart of “Pharma Bro” Martin Shkreli’s price-gouging notoriety, is changing hands once again.
Vyera Pharmaceuticals — formerly known as the Shkreli company Turing Pharmaceuticals — and its parent company Phoenixus struck a deal to sell Daraprim rights as part of its Chapter 11 bankruptcy proceedings. For $650,000, they will hand off both Daraprim and a hypertensive drug called Vecamyl and post-closing liabilities for the drugs, the companies announced on Tuesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
